Provided by Florence Research

Body Mass Index and Weight Gain in Pregnant Women With HIV: A National Study in Italy

Despite the growing number of human immunodeficiency virus (HIV)-infected women who are pregnant or planning a pregnancy, there is limited information on body weight status and weight gain in pregnancy in this population. The issue is relevant, because inadequate or excessive body mass index (BMI) and weight gain in pregnancy are risk factors for adverse pregnancy outcomes in the general population [1, 2], and may increase the risk of some events commonly observed among pregnant women with HIV, such as preterm delivery or glucose

Table 1. Body Mass Index Status at Conception and Weight Gain in Pregnancy

Characteristic	BMI (kg/m²) Status at Conception				
	Underweight (<18.5)	Normal (18.5–24.9)	Overweight (25.0–29.9)	Obese (≥ 30)	All
No. (%)	54 (7.3)	511 (69.4)	125 (17.0)	46 (6.3)	736 (100)
Recommended total weight gain during pregnancy ^a , kg	12.5–18.0	11.5–16.0	7.0–11.5	5.0-9.0	
Weight gain during pregnancy, kg, mean (SD)	12.5 (4.2)	11.6 (4.1)	10.5 (5.5)	9.1 (7.3)	11.4 (4.6)
Weight gain per wk, kg, mean (SD)	0.339 (0.12)	0.315 (0.11)	0.283 (0.14)	0.246 (0.20)	0.308 (0.12)
Weight gain during pregnancy					
Inadequate	26 (48.1)	265 (51.9)	29 (23.2)	10 (21.7)	330 (44.8)
Adequate	25 (46.3)	188 (36.8)	46 (36.8)	13 (28.3)	272 (37.0)
Excessive	3 (5.6)	58 (11.4)	50 (40.0)	23 (50.0)	134 (18.2)
Weight gain <0.100 kg/wk	1 (1.9)	4 (0.8)	10 (8.0)	10 (21.7)	25 (3.4)
Weight gain >0.400 kg/wk	16 (29.6)	97 (19.0)	20 (16.0)	10 (21.7)	143 (19.4)
Weight gain <5 kg	1 (1.9)	10 (2.0)	14 (11.2)	10 (21.7)	35 (4.8)
Weight gain >18 kg	3 (5.6)	30 (5.9)	11 (8.8)	4 (8.7)	48 (6.5)

Data are No. (%) unless otherwise specified.

Abbreviations: BMI, body mass index; SD, standard deviation.

metabolism abnormalities [3, 4]. We investigated BMI status, weight gain in pregnancy, and gestational outcomes within the Italian National Program on Surveillance on Antiretroviral Treatment in Pregnancy, a large cohort study of pregnant women with HIV [5].

All information was taken from clinical records. Given the variability in screening procedures and diagnostic criteria for gestational diabetes during the 10-year interval considered, we used a restrictive definition that considered among the recent American Diabetes Association criteria [6] only fasting plasma glucose levels >92 mg/dL at 20-28 weeks. Preterm delivery was defined as delivery before 37 completed weeks of gestation and low birthweight as neonates weighing <2500 g. Cesarean delivery was considered nonelective if performed after the rupture of membranes, the onset of labor, or both. Birth defects were defined according to the Antiretroviral Pregnancy Registry criteria [7], and sex-adjusted and gestational age-adjusted birthweight percentiles were calculated according to Italian reference standards [8]. The associations between potentially predictive variables and pregnancy outcomes were assessed using univariate logistic regression, and were expressed as odds ratios (ORs) and 95% confidence intervals (CIs).

Data were extracted from the study database on 25 July 2012. At this time, 736 pregnancies with live births had available information on BMI and weight gain in pregnancy and were therefore analyzed. The BMI categories (underweight, normal, overweight, obese) of the population studied and the pregnancy weight gain for each BMI category, including proportions of women meeting the Institute of Medicine recommendations for weight gain in pregnancy [9], are shown in Table 1.

Although most of the women (69.4%) had a normal BMI at start of pregnancy, only 37% had an adequate weight gain during pregnancy. Inadequate body weight gain was more common (44.8%) than excessive weight gain (18.2%), but 40% of overweight women and 50% of

obese women had an excessive weight gain in pregnancy, with about 9% of the women in these categories gaining >18 kg during pregnancy (Table 1).

Only 1.9% of the women had a vaginal delivery; elective and nonelective cesarean deliveries accounted for 81.3% and 16.7% of deliveries, respectively. Compared to underweight/normal women, overweight/obese women had similar occurrences of preterm delivery (23.4% vs 22.7%, P = .871), significantly lower rates of low birthweight (14.2% vs 24.2%, P = .007) and nonelective cesarean deliveries (11.7% vs 18.3%, P = .042), and a significantly higher occurrence of fasting plasma glucose >92 mg/dL at 20-28 weeks (12.1% vs 6.6%, P = .027), hypertension during pregnancy (6.4% vs 2.7%, P = .019), and gestational age-adjusted birthweight >90th percentile (15.5% vs 5.0%, P < .001). Complications of delivery, major birth defects, and HIV transmission were similar between the 2 groups (7.3% vs 7.6%, P = .881; 2.6% vs 3.5%, P = .589; and 0.8% vs 0.5%, P = .661, respectively).

^a Institute of Medicine recommendations [9].

An inadequate weight gain during pregnancy was associated with an increased risk of nonelective cesarean delivery (OR, 1.589 [95% CI, 1.077-2.346], P = .020). Excessive weight gain during pregnancy was not associated with either hypertension (OR, 1.364 [95% CI, .537-3.465], P = .514) or 20–28 week glucose level of >92 mg/dL (OR, 0.841 [95% CI, .399-1.772], P = .648), but was significantly associated with birthweight >90th percentile (OR, 2.271 [95% CI, 1.229-4.195], P = .009), and appeared to be protective against low birthweight (OR, 0.544 [95% CI, .323–.918], P = .023) and birthweight <10th percentile (OR, 0.297 [95% CI, .117–.752], P = .007).

Our data show that almost onequarter of pregnant women with HIV are overweight or obese at the beginning of pregnancy, and that women in these groups have a significantly increased occurrence of diabetes and hypertension in pregnancy. The risks of low birthweight and nonelective cesarean delivery were higher in the underweight/normal BMI categories. Consistent with data from the general population [10], only 37% of pregnant women with HIV had an adequate weight gain in pregnancy. Excessive weight gain during pregnancy was particularly frequent among overweight and obese women. Inadequate weight gain was associated with nonelective cesarean delivery, and excessive weight gain with large-for-gestational-age infants. BMI and weight gain represent modifiable risk factors that should be adequately identified and corrected in order to reduce adverse pregnancy outcomes in this population.

Notes

Acknowledgments. We thank Cosimo Polizzi and Alessandra Mattei of the Istituto Superiore di Sanità in Rome, Italy, for providing technical secretarial for this study.

Financial support. This work was supported by the Italian Medicines Agency (public research grant H85E08000200005).

Potential conflicts of interest. All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Marco Floridia, ¹ Marina Ravizza, ² Giulia Masuelli, ³ Serena Dalzero, ² Carmela Pinnetti, ⁴ Irene Cetin, ⁵ Alessandra Meloni, ⁶ Arsenio Spinillo, ⁷ Elena Rubino, ⁸ Daniela Francisci, ⁹ and Enrica Tamburrini; ¹⁰ for the Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy ^a

¹Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Rome; ²Department of Obstetrics and Gynaecology, S. Paolo Hospital, Milan; ³Department of Obstetrics and Neonatology, Città della Salute e della Scienza Hospital, and University of Turin; ⁴National Institute of Infectious Diseases "Lazzaro Spallanzani," Rome; ⁵Department of Obstetrics and Gynaecology, Luigi Sacco Hospital, University of Milan; ⁶Department of Obstetrics and Gynaecology, S. Giovanni di Dio Hospital, Cagliari; ⁷Department of Obstetrics and Gynaecology, IRCCS "S. Matteo," Pavia; 80bstetrics and Gynaecology Clinic, University of Palermo; 9Clinic of Infectious Diseases, Department of Experimental Medicine and Biochemical Sciences, University of Perugia; and ¹⁰Department of Infectious Diseases, Catholic University, Rome, Italy

References

- Mamun AA, Callaway LK, O'Callaghan MJ, et al. Associations of maternal pre-pregnancy obesity and excess pregnancy weight gains with adverse pregnancy outcomes and length of hospital stay. BMC Pregnancy Childbirth 2011; 11:62.
- Watanabe H, Kabeyama K, Sugiyama T, Fukuoka H. A review of inadequate and excessive weight gain in pregnancy. Curr Womens Health Rev 2009; 5:186–92.
- Townsend C, Schulte J, Thorne C, et al. Antiretroviral therapy and preterm delivery—a pooled analysis of data from the United States and Europe. BJOG 2010; 117: 1399–410.
- González-Tomé MI, Ramos Amador JT, Guillen S, et al. Gestational diabetes mellitus in a cohort of HIV-1 infected women. HIV Med 2008; 9:868–74.
- Floridia M, Ravizza M, Tamburrini E, et al. Diagnosis of HIV infection in pregnancy: data from a national cohort of pregnant women with HIV in Italy. Epidemiol Infect 2006; 134:1120–7.
- International Association of Diabetes and Pregnancy Study Groups. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010; 33:676–82.
- Scheuerle A, Tilson H. Birth defect classification by organ system: a novel approach to heighten teratogenic signalling in a pregnancy

- registry. Pharmacoepidemiol Drug Saf **2002**; 11:465–75.
- Bertino E, Spada E, Occhi L, et al. Neonatal anthropometric charts: the Italian neonatal study compared with other European studies. J Pediatr Gastroenterol Nutr 2010; 51:353-61.
- Institute of Medicine and National Research Council Committee to Reexamine IOM Pregnancy Weight Guidelines; Rasmussen KM, Yaktine AL, eds. Weight gain during pregnancy: reexamining the guidelines. Washington, DC: National Academies Press, 2009.
- Stotland NE, Cheng YW, Hopkins LM, Caughey AB. Gestational weight gain and adverse neonatal outcome among term infants. Obstet Gynecol 2006; 108:635–43.

Appendix

The Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy

Project coordinators: M. Floridia, M. Ravizza, E. Tamburrini.

Participants: M. Ravizza, E. Tamburrini, F. Mori, P. Ortolani, E. R. dalle Nogare, F. Di Lorenzo, G. Sterrantino, M. Meli, S. Polemi, J. Nocentini, M. Baldini, G. Montorzi, M. Mazzetti, P. Rogasi, B. Borchi, F. Vichi, E. Pinter, E. Anzalone, R. Marocco, C. Mastroianni, V. S. Mercurio, A. Carocci, E. Grilli, A. Maccabruni, M. Zaramella, B. Mariani, G. Natalini Raponi, G. Guaraldi, K. Luzi, G. Nardini, C. Stentarelli, A. M. Degli Antoni, A. Molinari, M. P. Crisalli, A. Donisi, M. Piepoli, V. Cerri, G. Zuccotti, V. Giacomet, V. Fabiano, G. Placido, A. Vivarelli, P. Castelli, F. Savalli, V. Portelli, F. Sabbatini, D. Francisci, L. Bernini, S. Alberico, G. Maso, M. Tropea, A. Meloni, M. Dedoni, C. Cuboni, F. Ortu, P. Piano, A. Citernesi, I. Vicini, A. Spinillo, M. Roccio, A. Vimercati, A. Miccolis, E. Bassi, B. Guerra, F. Cervi, C. Puccetti, P. Murano, M. Contoli, M. G. Capretti, C. Marsico, G. Faldella, M. Sansone, P. Martinelli, A. Agangi, C. Tibaldi, L. Trentini, T. Todros, G. Masuelli, S. Garetto, I. Cetin, T. Brambilla, V. Savasi, A. Crepaldi, C. Giaquinto, M. Fiscon, R. Rinaldi, E. Rubino, A. Bucceri, R. Matrone, G. Scaravelli, C. Fundarò, O. Genovese, C. Cafforio, C.

Pinnetti, G. Liuzzi, V. Tozzi, P. Massetti, M. Anceschi, A. M. Casadei, A. F. Cavaliere, V. Finelli, M. Cellini, G. Castelli Gattinara, A. M. Marconi, S. Dalzero, V. Sacchi, A. De Pirro, C. Polizzi, A. Mattei, M. F. Pirillo, R. Amici, C. M. Galluzzo, S. Donnini, S. Baroncelli, M. Floridia.

Pharmacokinetics: M. Regazzi, P. Villani, M. Cusato.

Advisory Board: A. Cerioli, M. De Martino, P. Mastroiacovo, M. Moroni, F. Parazzini, E. Tamburrini, S. Vella. SIGO-HIV Group National Coordinators: P. Martinelli, M. Ravizza.

Clinical Infectious Diseases 2013;56(8):1190-3

© The Author 2013. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals. permissions@oup.com.

DOI: 10.1093/cid/cis1225

^aMembers of the Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy are listed in the Appendix.

Correspondence: Marco Floridia, Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy (marco. floridia@iss.it).